Geode Capital Management LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Geode Capital Management LLC bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 891,407 shares of the company's stock, valued at approximately $3,229,000. Geode Capital Management LLC owned 1.06% of Atyr PHARMA at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $36,000. Victory Capital Management Inc. bought a new stake in Atyr PHARMA during the 4th quarter valued at about $37,000. Raymond James Financial Inc. purchased a new stake in Atyr PHARMA in the 4th quarter valued at about $39,000. JPMorgan Chase & Co. grew its stake in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after acquiring an additional 10,754 shares in the last quarter. Finally, Farther Finance Advisors LLC purchased a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $88,000. Institutional investors own 61.72% of the company's stock.

Atyr PHARMA Stock Up 7.8 %

Shares of ATYR stock traded up $0.26 during mid-day trading on Friday, hitting $3.60. 1,375,066 shares of the stock traded hands, compared to its average volume of 905,107. The stock's fifty day moving average is $3.29 and its two-hundred day moving average is $3.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The stock has a market cap of $319.89 million, a P/E ratio of -3.83 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. Equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Friday, March 14th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating on the stock. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.